Each week, we like to take a moment to boil down the biggest news from the most influential companies in the pharmaceuticals industry and tell our viewers what that news means for you. We call that segment our Big Pharma Roundup.
In this week's installment, Johnson & Johnson (NYSE: JNJ) saw its Fibrin Pad receive FDA approval recently. The pad stops bleeding by promoting blood clots and gives the company further exposure to the $3 billion wound-closure market. In this video, Motley Fool health-care analyst Brenton Flynn tells investors how the approval is going to affect them.
In the world of health care, companies simply don't come any bigger than Johnson & Johnson. Many own the stock, but few understand its story. Offering everything from baby powder to biologics, critics think the company has spread itself too thin, becoming nothing more than a bloated corporate whale. Is this true, or is J&J a well-diversified giant that's perfect for your portfolio? Make sure you understand the full story behind the stock, along with its key opportunities and risks, by checking out our brand-new premium report on Johnson & Johnson. To claim your copy, simply click here now for instant access.